

Jenny Bulgarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5530695/publications.pdf>

Version: 2024-02-01

27
papers

405
citations

933447

10
h-index

794594

19
g-index

28
all docs

28
docs citations

28
times ranked

960
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center. <i>Vaccines</i> , 2022, 10, 999. | 4.4 | 3 |
| 2 | Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic Syndrome. <i>Nutrients</i> , 2021, 13, 2081. | 4.1 | 5 |
| 3 | Abstract 2776: Sequential immunohistochemistry and computational image analysis for a deeper characterization of tumor-infiltrating myeloid cells. , 2021, , . | | 0 |
| 4 | 381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax). <i>Annals of Oncology</i> , 2021, 32, S529. | 1.2 | 0 |
| 5 | Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 778459. | 4.8 | 6 |
| 6 | 49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results. <i>Annals of Oncology</i> , 2021, 32, S1394. | 1.2 | 0 |
| 7 | 832...Unravelling human melanoma heterogeneity by 6-color multiplex immunofluorescence to overcome recurrence and resistance to therapy. , 2020, , . | | 0 |
| 8 | Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353. | 4.8 | 22 |
| 9 | The ACC melanoma pilot project: "Real-world" evaluation of an NGS platform for molecular characterization of melanoma in Italy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14600-e14600. | 1.6 | 0 |
| 10 | Radiotherapy as an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-Dose Interleukin-2: Final Data. <i>Annals of Oncology</i> , 2019, 30, xi44-xi45. | 1.2 | 0 |
| 11 | Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433. | 1.3 | 7 |
| 12 | Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone. <i>Cytotherapy</i> , 2018, 20, 851-860. | 0.7 | 3 |
| 13 | Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC) Tj ETQq1 1 0.7843 14rgBT /Overlock | | |
| 14 | Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. <i>Melanoma Research</i> , 2017, 27, 351-357. | 1.2 | 14 |
| 15 | Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262. | 3.5 | 40 |
| 16 | MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. <i>Cell Death and Differentiation</i> , 2015, 22, 1906-1921. | 11.2 | 60 |
| 17 | Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: Interim analysis data.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14007-e14007. | 1.6 | 3 |
| 18 | Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818. | 2.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1. | 0.4 | 23 |
| 20 | Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3286-3286. | 1.4 | 0 |
| 21 | C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf. <i>Blood</i> , 2014, 124, 5124-5124. | 1.4 | 0 |
| 22 | The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123. | 3.5 | 92 |
| 23 | <i>ANGPT2</i> promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729. | 2.7 | 30 |
| 24 | Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95. | 1.7 | 25 |
| 25 | Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960. | 3.5 | 29 |
| 26 | In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782. | 1.4 | 2 |
| 27 | A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. <i>Blood</i> , 2011, 118, 1782-1782. | 1.4 | 0 |